Drugs / KN044
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04126590 | Jan 2020 → Jun 2024 | cancer | Changchun Intellicrown Pharmaceutical Co. LTD | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KN044 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04126590 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Humanized Cytotoxic T Lymphocyte Antigen 4 Single Domain Antibody Fc Fusion Protein Injection” NCT04126590 ↗ |
| Route | Intravenous | “KN044 will be antimedical intravenously over 30 minutes” NCT04126590 ↗ |